Lymphocyte transfusion from the marrow donor (DLT) is well established as an effective therapy for relapse of CML post allogeneic BMT. Reports thus far have been mostly limited to patients who received DLT from a matched sibling donor. We compared the efficacy and toxicity of DLT in 30 patients who were treated with cells from their HLA-identical sibling (n = 18) or from their phenotypically HLA-matched unrelated marrow donor (n = 12). The overall probability of obtaining a cytogenetic remission was 69% (95%CI: 51-83%) and was not significantly different between the two groups. The disease stage at the time of DLT was the only factor associated with cytogenetic remission by multivariate analysis; patients treated in cytogenetic or molecular relapse (n = 11) were seven times more likely (RR = 7.4, 95%CI: 2.4-22.4, P = 0.0005) to respond compared to patients treated for hematologic relapse (n = 19). There was a trend towards more acute GVHD II-IV in the unrelated donor group (58 vs 39%, P = 0.09), but the probability of developing extensive chronic GVHD was not significantly different (56 vs 39%, P = 0.4). We conclude that transfusion of donor cells from HLAmatched volunteer donors does not appreciably increase the risk of GVHD compared with transfusion of cells from HLA-identical siblings in patients with CML who relapse following allogeneic BMT. Conversely, there is no evidence for an increased graft-versus-leukemia effect after DLT from volunteer donors.
cyclosporin A and methotrexate (MTX), and more efficacious prevention and treatment of cytomegalovirus infection. 4, 5 However, leukemia relapse continues to occur in 10-20% of patients transplanted with unmanipulated marrow cells. 6, 7 A number of recent studies suggest that it is possible to induce remissions in the majority of patients with CML in relapse by transfusing immunocompetent cells from the marrow donor. Although adoptive immunotherapy with donor lymphocytes has proven effective, it is complicated by GVHD in approximately 60% of patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The reported experience with this new form of treatment has been mainly confined to patients who were transfused with cells from sibling donors. Only 30-40% of patients have a genotypically HLA-identical donor available for allogeneic marrow grafting. The creation of large unrelated marrow donor registries has made it possible to identify a phenotypically HLA-matched donor in approximately onethird of the remaining patients. As a result, marrow cells from matched unrelated donors (UD) are used with increasing frequency for allogeneic BMT. However, a high incidence of GVHD has been reported after BMT using marrow cells obtained from a matched volunteer donor. 20, 21 This is thought to be due to polymorphic differences at HLA loci and increased mismatching for minor histocompatibility antigens. 22 There is therefore also the potential for more GVHD in the setting of adoptive immunotherapy for relapse using allogeneic lymphocytes collected from unrelated marrow donors. We examined the outcome of 30 consecutive patients who were treated with DLT from either a sibling or unrelated donor at a single institution.
Patients and methods

Patients
Thirty patients with relapsed CML after BMT received DLT from their marrow donor (sibling n = 18, unrelated n = 12). Twenty-eight patients were treated for relapse of Philadelphia chromosome positive CML and two for relapse of Philadelphia negative, BCR-ABL positive CML. Twenty-six patients were in first chronic phase at the time of BMT; two had accelerated phase disease. Two patients underwent two transplant procedures for accelerated and chronic phase disease, respectively. All sibling donor-recipient pairs were HLA-identical. Twenty-seven patients were conditioned with cyclophosphamide (CY) and fractionated TBI (10 Gy, n = 1; 12 Gy, n = 14; and 13.2 Gy, n = 12) as previously described. 23 Two patients had been conditioned with busulphan (BU) alone and 1 received BU/CY. Eight patients transplanted from a sibling donor received grafts which were T cell depleted using Campath-1 antibodies (ex vivo, n = 4; in vivo, n = 4). In the unrelated donor group two patients received ex vivo T cell-depleted marrow and 10 were treated intravenously with Campath-1G. Twelve patients were treated with lymphocytes from their unrelated marrow donor (cytogenetic relapse/molecular relapse n = 5; chronic phase relapse n = 5, accelerated phase relapse n = 2). The unrelated donor-recipient pairs were all serologically matched. All 12 donor-recipient pairs were compatible at class I loci by iso-electric focusing and at class II loci by DR␤1 typing. Molecular typing for HLA class I was not carried out.
Cytogenetic analysis
Bone marrow metaphase preparations were studied by Gbanding for the presence of the Philadelphia chromosome. At least 30 metaphases were examined whenever possible. Bone marrow examinations were carried out at 3-monthly intervals after the primary transplant. Patients who were PCR positive and high (Ͼ1000 BCR-ABL transcripts/g RNA) or rising BCR-ABL transcript levels on sequential analyses had marrow examinations at intervals of 2 months.
Competitive PCR for BCR-ABL mRNA
Post BMT peripheral blood samples were studied at 3-monthly intervals for BCR-ABL transcripts by two-step RT-PCR with nested primers as previously described. 24 For PCR positive samples, the number of BCR-ABL transcripts was semi-quantitatively estimated by competitive PCR at intervals of 2 months. 25 The frequency of cytogenetic and PCR monitoring of relapsing leukemia after the primary transplant and after lymphocyte transfusion was similar in both the sibling and unrelated donor group.
Definition of relapse
Hematologic relapse was defined as peripheral blood leucocytosis with predominance of myelocytes and neutrophils in the differential count. This was accompanied by a hypercellular bone marrow and Philadelphia positive metaphases on cytogenetic analysis. Cytogenetic relapse was considered to be present if one or more Philadelphia positive metaphases were detected without evidence of hematologic relapse. Molecular relapse was defined as more than 1000 BCR-ABL transcripts/g RNA detected in the blood by competitive PCR more than 4 months after transplant without evidence of cytogenetic or hematologic relapse.
Management of relapse
Treatment of relapse prior to DLT consisted of hydroxyurea (n = 4) or ␣-interferon (n = 4). Only one of the four patients treated with ␣-interferon prior to DLT obtained a cytogenetic response. Seven patients were receiving cyclosporin A at the time of relapse. All these patients had leukemia relapse, but no evidence of graft failure or graft rejection. Cyclosporin A was therefore withdrawn only for treatment of relapse. No response to cessation of cyclosporin A was observed in these seven patients. The remaining patients were not on cyclosporin A therapy at the time of relapse.
Collection of donor cells
Donor cells were collected on a continuous flow cell separator (COBE Spectra, Gloucester, UK) and transfused immediately into the recipient. Plasma or red cell depletion for ABO-incompatibility was not performed. The leukocytes collected from unrelated donors were provided by the Anthony Nolan Panel (n = 10), British Bone Marrow and Platelet Donor Panel (n = 1) and National Marrow Donor Program in the USA (n = 1). Donors were leukapheresed on an average of two occasions (range 1-4) with a maximum interval of 16 days between collections. The nucleated cell and lymphocyte doses administered are shown in Table 1 . Four patients were treated prophylactically with cyclosporin A after receiving leukocytes from Table 1 Characteristics of 30 patients with relapsed CML following allogeneic BMT who were treated with lymphocyte transfusion from a sibling or unrelated donor a Nine patients with Ph chromosome in marrow metaphases; two were cytogenetically normal but had high levels of BCR-ABL transcripts in blood (5000 and 30 000 transcripts/g RNA respectively). b Multiple cytogenetic abnormalities characteristically associated with disease acceleration and/or a platelet count Ͼ1000 × 10 9 /l. their respective unrelated donors. Interferon-␣ was not administered in conjunction with the donor lymphocytes.
Definition of response
A cytogenetic remission was recorded when the peripheral blood counts had normalized with no morphological evidence of CML in the bone marrow and no Philadelphia positive metaphases were detected on cytogenetic analysis of the bone marrow. Cytogenetic analysis post lymphocyte transfusion was performed at minimum intervals of 3 months until cytogenetic remission was documented. In the two patients with molecular relapse complete remission was defined as a 2 log reduction in the level of BCR-ABL transcripts. Molecular remission was deemed to be present if BCR-ABL transcripts were not detected by two-step PCR with nested primers subject to satisfactory controls. PCR analysis post lymphocyte transfusion was performed at minimum intervals of 3 months.
Acute and chronic GVHD
These were graded according to standard criteria. 26, 27 Chronic GVHD was diagnosed if GVHD occurred de novo or persisted for more than 100 days after leukocyte transfusion. 'Marrow aplasia' was defined by a hypocellular bone marrow with peripheral blood pancytopenia (Hb Ͻ 11g/dl, neutrophils Ͻ 0.5 × 10 9 /l and platelets Ͻ50 × 10 9 /l).
Statistics
Fisher's exact test and the Mann-Whitney tests were employed to compare that groups were appropiate. Outcome probabilities were calculated by the method of Kaplan and Meier. To test the association between prognostic and outcome variables, the log-rank test was used for univariate analyses, and proportional hazards analysis for multivariate associations. Prognostic variables considered were disease stage, patient/donor sex and age, GVHD prophylaxis regimen, and transfused mononuclear and lymphocyte dose. The Spearman rank correlation coefficient was calculated for the association between lymphocyte dose and time to response in the complete responders. All quoted P values are two-sided, and confidence intervals refer to 95% boundaries.
Results
Response
The median time from detection of cytogenetic or hematologic relapse to leukocyte transfusion was 10.9 months (range 0-69.9). The median follow-up after DLT was 22.2 months (range 1.5-69.9). Of 30 relapsing patients receiving DLT, 20 (66.7%) achieved a cytogenetic remission. One previously reported patient with hematologic relapse responded to DLT only after the addition of ␣-interferon therapy. 28 The probability of obtaining a cytogenetic remission at 2 years post lymphocyte transfusion was 69.3% (95% CI: 51-83) (Figure 1 ). The median time to cytogenetic remission in the responders was 118 days (range 33-145). Molecular remissions with no detectable BCR-ABL transcripts were documented in 16 of 20 responders. The probability of obtaining a molecular remission at 2 years after DLT was 60% (95% CI: 39-78) (Figure 1) . Three of the four patients who have not attained PCR negativity have falling transcript levels at 7.4, 10.4 and 12.2 months, respectively. The three longest responders remain PCR negative 45, 58 and 63 months, respectively, after transfusion of donor leukocytes. The median time to molecular remission was relatively long at 306 days (range: 77-972). This may be due, at least in part, to the fact that PCR analyses were performed less frequently in five patients who had either intervals of more than 4 months between PCR assays or were first studied more than 4 months post lymphocyte transfusion. The median time to molecular remission was 222 days (range 77-792) when these patients were excluded from analysis.
Comparison of response in unrelated and sibling donor group
The patients receiving unrelated donor cells were well matched with the sibling donor group with respect to disease stage, patient/donor age and patient sex, incidence of acute and chronic GVHD post BMT, interval from first detection of relapse to DLT, and cell dose transfused ( Table 1 ). The interval from BMT to the first detection of relapse was significantly shorter in the unrelated donor group (9.1 vs 30.0 months, P = 0.005). This difference can be explained by the more frequent ex vivo or in vivo T cell depletion of the marrow graft in the unrelated donor group (P = 0.002). There was no significant difference in the probability of attaining a cytogenetic remission in the unrelated donor and sibling donor group (64.0%, CI: 34-87 vs 73.3%, CI: 50-89, respectively; P = 0.71) (Figure 2 ). The median interval to a cytogenetic remission in the sibling donor and unrelated group was 124 days (range 55-145) and 100 days (range 33-140), respectively (P = 0.71). All seven responders in the unrelated donor group achieved a molecular remission. Thirteen patients in the sibling donor group responded and nine entered a molecular remission. The probabilities of obtaining a molecular remission at 2 years in both groups were not significantly different (probabilities are 55%, 95% CI: 22-70 and 65%, 95% CI: 34-87, respectively). The median intervals to a molecular remission in the sibling and unrelated donor groups were 444 days (range 80-712) and 263 days (range 77-972), respectively (P = 0.41). Prophylactic cyclosporin A was administered for 4-12 weeks to the first four patients receiving cells from an unrelated donor; responses were only observed after cyclosporin A had been withdrawn. Subsequent patients did not receive prophylactic cyclosporin A.
Factors associated with response
All 11 patients in cytogenetic or molecular relapse at the time of transfusion responded, but a cytogenetic remission was noted in only nine (50%) of 18 patients with hematologic relapse. Only one of the five patients with relapsed CML in accelerated phase achieved a cytogenetic remission. The probability of achieving a cytogenetic remission for patients with cytogenetic/molecular relapse and relapse into chronic phase was 100 and 63%, respectively ( Figure 3 ). Disease stage influenced the response rate significantly in univariate analysis (P = 0.001). Patients who did not develop chronic GVHD after BMT were more likely to achieve a complete remission after DLT. Seventeen (81%) of 21 patients who had no or limited chronic GVHD post BMT achieved cytogenetic remission compared to three (38%) of eight patients with extensive chronic GVHD (P = 0.03). Absence of grade II-IV acute GVHD after the primary transplant was not associated with response to DLT. Ten of 13 (77%) patients who developed acute GVHD II-IV post DLT responded to treatment compared to six of 16 (38%) patients with acute GVHD grade 0-I (P = 0.04). The occurrence of chronic GVHD post DLT was not associated with response. The only factor which was associated with response in multivariate analysis was the disease stage at the time of DLT. Patients receiving DLT for cytogenetic/molecular relapse were seven times more likely to achieve a cytogenetic remission (RR = 7.4, 95% CI 2.4-22.4; P = 0.0005) than patients treated in hematologic relapse. T cell depletion, irrespective of stem cell source, was not significantly associated with response in multivariate analysis.
Durability of response
The remissions in the responder group are durable and no second cytogenetic or hematologic relapses have occurred. In 4 patients positive PCR assays have been observed after initial PCR negativity had been obtained. In three patients transcripts have been found at the borderline level of detection (Ͼ10 BCR-ABL transcripts/g RNA), but these patients have subsequently again become PCR negative. The fourth patient had a rise in transcript levels to 210 BCR-ABL transcripts/g RNA, but was PCR negative at the last follow-up, 21 months after lymphocyte transfusion. A fifth patient entered complete cytogenetic remission, but did not become PCR negative. The lowest transcript level measured in this patient was Ͻ10 BCR-ABL transcripts/g RNA. This patient has experienced a rise in transcript levels to 5.3 × 10 3 BCR-ABL transcripts/g RNA, but has no other evidence of progression.
Acute GVHD
Grade II-IV acute GVHD occurred in 14 out of 30 (47%) patients. The probability of developing grade II-IV acute GVHD was 47% (95% CI: 30-64). Nine patients developed grade III-IV acute GVHD. Of these nine patients two have died and seven are alive. Five of these seven patients are alive with extensive chronic GVHD; the remaining two have responded to therapy and are currently well without GVHD.
Chronic GVHD
Chronic GVHD developed in 14 of 29 (49%) patients. The probability of developing limited or extensive chronic GVHD at 180 days post DLT was 49.1% (95% CI: 32-67). All patients who developed chronic GVHD had done so by this time. Of 11 patients with extensive chronic GVHD post DLT, one has died and 10 are currently alive. Eight patients are still receiving treatment for chronic GVHD at a median of 11.6 months post DLT (range 8.9-68.8). Overall, five patients entered complete remission without developing acute or chronic GVHD.
Comparison of GVHD in sibling and unrelated donor group
Grade II-IV occurred in seven of 12 (58%) patients after DLT in the unrelated donor group compared to seven of 18 (39%) patients in the sibling donor group. There was a trend towards a higher probability of acute GVHD post DLT from an unrelated donor (58.3%, 95% CI 32-80 vs 38.9%, 95% CI 20-62; P = 0.09) (Figure 4) . Extensive chronic GVHD occurred in six of 11 (55%) patients eligible for GVHD in the unrelated group and five of 18 (28%) patients in the sibling donor group. The probabilities of developing extensive chronic GVHD in both groups were not significantly different (56%, 95% CI: 19-72 vs 34%, 95% CI: 17-57).
Marrow aplasia
Marrow aplasia was observed in five of 19 patients treated for hematologic relapse, but in none of 11 patients treated in cytogenetic or molecular relapse. Four of five patients with marrow aplasia attained a complete cytogenetic remission and eventually established donor hematopoiesis in the bone marrow. Three patients received a marrow cell transfusion without prior conditioning therapy; a fourth patient had spontaneous recovery of donor hematopoiesis. The fifth patient died of severe acute GVHD before a response could be evaluated.
Mortality
The probability of survival at 2 years post DLT was 89% (95% CI: 72-96). Four patients died after DLT. Three were non-responders and one patient died with aplasia before response could be evaluated. The probability of death at 2 years after DLT was 11.5% (95% CI: 4-28). The first patient died 1.5 months after DLT from an unrelated donor from severe acute GVHD whilst in marrow aplasia. The second patient had not responded and died 6.9 months after DLT from a sibling donor of sepsis and the complications of a liver biopsy for severe liver GVHD. The third patient died in relapse 20.3 months after DLT. The fourth patient had not responded to DLT and declined further medical treatment. This patient died 30 months after DLT, probably due to transformation of CML. 
Discussion
Adoptive immunotherapy with donor cells has emerged as the first line of therapy for relapse of CML post allogeneic transplant and has proven an effective alternative to a second transplant. The experience with this new treatment modality has been mainly limited to patients transfused with cells from identical sibling donors. There is reason to expect a more potent graft-versus-leukemia effect using allogeneic lymphocytes from an unrelated donor. Several studies have drawn attention to the low relapse rate of CML using T cell-depleted marrow cells from unrelated donors in contrast to the high relapse rates after T cell-depleted sibling BMT. 21, [29] [30] [31] [32] A recent study reported that use of an unrelated donor is also associated with a reduced risk of relapse of CML after transplant with unmanipulated marrow cells. 7 The protective effect of an unrelated donor has been attributed to an enhanced graft-versus-leukemia effect caused by differences in fine specificities at HLA loci and increased mismatching for minor histocompatibility antigens. It might therefore be speculated that the increase in GVL reactivity between unrelated donors and recipients would also lead to a higher response rate to lymphocyte transfusions administered for relapse after transplant. In this series, complete cytogenetic or molecular responses were observed in 20 of 30 patients. The overall probability of obtaining a cytogenetic remission was 69%. The response rate and the time to cytogenetic remission was very similar in the unrelated and sibling donor groups, suggesting that there was no enhancement of the graft-versus-leukemia effect with use of lymphocytes from an unrelated donor. However, the number of patients in both the unrelated and sibling donor group was relatively small, and it cannot be excluded that study of larger cohorts might still reveal a difference in response. The best predictor for response was the stage of disease at the time of DLT. Patients who were treated before hematologic relapse had become established were seven times more likely to respond compared to patients treated for clinical relapse.
GVHD is the most important complication of adoptive immunotherapy with donor cells. In this series the probabilities of developing acute or chronic GVHD post DLT were 47 and 49%, respectively. It is well established that the incidence of severe GVHD is increased after BMT from unrelated donors. 20, 21 Severe GVHD has recently been reported following DLT from mismatched family members. 33, 34 In the present series there was a trend towards more acute GVHD after DLT from an unrelated donor. However, there were no significant differences in either acute or chronic GVHD between the unrelated and sibling donor groups. This is perhaps surprising taking into account that the recipients of cells from an unrelated donor were more likely to have received T cell depletion at the time of primary transplant and had a shorter median interval from BMT to DLT (22 vs 49 months). These parameters could be expected to enhance any GVHD in the recipients of lymphocytes from an unrelated donor in this study. 15 The fact that there was no increase in GVHD in the unrelated donor cohort suggests that it is feasible to transfuse donor cells in phenotypically closely matched unrelated donorrecipient pairs. These data are in agreement with the recently reported North-American DLT experience which also found no assocation between donor type and GVHD. 35 Overall the probability of a molecular remission at 2 years post DLT was 60%. The median time to obtaining a molecular remission was 306 days which indicates that the elimination of the leukemic clone after DLT is very gradual, at least in some cases. This bears some resemblance to the situation post BMT in which residual Philadelphia positive cells can be demonstrated in many patients for 6-12 months post BMT. [36] [37] [38] The median follow-up on the DLT patients is 22 months and the three longest responders have been in molecular remission for over 5 years. This indicates that the responses to DLT were durable. However, it should be noted that the longevity of the transfused lymphocytes is as yet uncertain and it cannot be ruled out that very late relapses may still occur. The adoptive transfer of gene-marked EBV specific cytotoxic T cell lines in patients at risk for EBV lymphoproliferative disorders post BMT suggests that EBV reactive T cells can persist in vivo and re-expand if challenged by the appropriate antigen for at least 18 months. 39 
